Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments

Background Clinical trials comparing the efficacy of ocrelizumab (OCR) with other disease-modifying therapies (DMTs) other than interferon (IFN) β-1a in relapsing multiple sclerosis (RMS) are lacking. Objectives To compare the treatment effect of OCR vs six DMTs’ (IFN β-1a, glatiramer acetate, fingo...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Erwan Muros-Le Rouzic, Yanic Heer, Sean Yiu, Viola Tozzi, Stefan Braune, Philip van Hövell, Arnfin Bergmann, Corrado Bernasconi, Fabian Model, Licinio Craveiro
Formato:	Artigo
Idioma:	Inglês
Publicado em:	SAGE Publishing 2024-06-01
coleção:	Journal of Central Nervous System Disease
Acesso em linha:	https://doi.org/10.1177/11795735241260563
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!